Pearl Steinzor

A legal fight over a single amino acid could set retatrutide's exclusivity window, its Medicare negotiation clock, and its competitive future.

Stutsky explains why shifting therapy perceptions had more pharmacist touchpoints and longer time on therapy among patients with ATTR-CM.

Moderate coffee intake may lower cardiovascular risk, but energy drinks may harm the heart.

The approval is based on findings from the phase 3 SCOUT-HCM trial.

Average stand-alone Part D premiums are projected to rise by less than $1 a month as a temporary subsidy program ends after 2026.

Pharmacy leaders examined AI for authorizations, adherence, patient access, and efficient specialty pharmacy benefits in health-system care.

The triple agonist also lowered HbA1C by up to 1.6% over 80 weeks, with up to 40% of participants reaching normal levels.

Symptom-tracking tools may improve awareness and patient-clinician communication but can also add stress.

Chester Good, MD, MPH, shares data and strategies used by UPMC to evaluate value-based contracting in specialty pharmacy.

Two posters report 3.9% first-year GLP-1 discontinuation and a 5-day median time to first fill under pharmacist-led care.

Sophy Levine, PharmD, discusses how an integrated health system specialty pharmacy may help lower 1-year GLP-1 discontinuation.

Adaolisa Anaka, PharmD, BCACP, AAHIVP, discusses a pharmacist-led model that targets access barriers to GLP-1 obesity therapy.

Irfana Lakada, PharmD, CSP, explains why onboarding may be the wrong time to screen for social needs and why rescreening matters.

Jesse Dresser explains how federal PBM reform, a new CMS RFI, and FTC settlements could reshape specialty pharmacy contracts and pay from 2027.

HYPERION trial data shows a 76% reduction in clinical worsening events among adults recently diagnosed with PAH.

Global Burden of Disease data show prevalence fell nearly 30% from 1990 to 2021, yet the number of women affected grew 9.1%.

Geeta Nayyar, MD, MBA, says AI's real health care payoff is cutting administrative friction with clean data and clinical leadership.

A 20-year Danish registry study found higher antidepressant and anxiolytic use among women with endometriosis, both before and after diagnosis.

Working-age adults with private insurance are paying off medical debt, often draining savings, delaying care, or cutting back on necessities as a result.

Alcohol abuse was the strongest post-trauma psychiatric predictor of cardiovascular events, with mood disorders more prominent among women.

Individuals with or at risk for arrhythmogenic cardiomyopathy had no added risk of ventricular arrhythmia from strength training, unlike endurance exercise.

Roundtables reveal HFpEF/HFmrEF care lags despite rising cases; learn new SGLT2/MRA strategies, screening, and scalable team pathways.

AACR urges Congress to protect NIH/NCI funding amid a fight over a contested OMB grantmaking rule.

Mark Belkin, MD, explains why HFpEF goes undiagnosed, how MRA evidence should guide therapy, and what's next for AI-driven care.

PBM practices and split benefit coverage for oral vs IV chemotherapy drive high costs; a bill would close the gap for self-funded plans.

Ann Marie Navar, MD, PhD, on enlicitide's 60% LDL reduction, less than 50% ApoB lowering, fasting dosing rules, and how it compares with inclisiran.

Endometriosis was found to nearly double absenteeism and work-ability impairment, according to one study.

The ESC's 2026 heart failure guidelines overhaul HF classification, rename therapy categories, and add a new HFpEF recommendation.

A multicenter study found guideline-based grading underestimates tricuspid regurgitation severity and risk in ATTR-CM.

A new iPSC-derived platform from patients with endometriosis captures the disease's molecular and hormonal features in a human context.